Assessing TP53 status in human tumours to evaluate clinical outcome - PubMed (original) (raw)

Review

Assessing TP53 status in human tumours to evaluate clinical outcome

T Soussi et al. Nat Rev Cancer. 2001 Dec.

Abstract

TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?

PubMed Disclaimer

Similar articles

• p53 family update: p73 and p63 develop their own identities.
  Irwin MS, Kaelin WG. Irwin MS, et al. Cell Growth Differ. 2001 Jul;12(7):337-49. Cell Growth Differ. 2001. PMID: 11457731 Review. No abstract available.
• Another p53 Doppelgänger?
  Kaelin WG Jr. Kaelin WG Jr. Science. 1998 Jul 3;281(5373):57-8. doi: 10.1126/science.281.5373.57. Science. 1998. PMID: 9679018 No abstract available.
• Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
  Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frébourg T. Bougeard G, et al. J Med Genet. 2001 Apr;38(4):253-7. doi: 10.1136/jmg.38.4.253. J Med Genet. 2001. PMID: 11370630 Free PMC article. No abstract available.
• The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
  Nylander K, Dabelsteen E, Hall PA. Nylander K, et al. J Oral Pathol Med. 2000 Oct;29(9):413-25. doi: 10.1034/j.1600-0714.2000.290901.x. J Oral Pathol Med. 2000. PMID: 11016683 Review.
• RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
  Stein T, Crighton D, Boyle JM, Varley JM, White RJ. Stein T, et al. Oncogene. 2002 May 2;21(19):2961-70. doi: 10.1038/sj.onc.1205372. Oncogene. 2002. PMID: 12082526

Cited by

• Household income is associated with the p53 mutation frequency in human breast tumors.
  Starks AM, Martin DN, Dorsey TH, Boersma BJ, Wallace TA, Ambs S. Starks AM, et al. PLoS One. 2013;8(3):e57361. doi: 10.1371/journal.pone.0057361. Epub 2013 Mar 1. PLoS One. 2013. PMID: 23469190 Free PMC article.
• Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
  Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A. Löffler H, et al. Oncotarget. 2016 Jul 12;7(28):44322-44329. doi: 10.18632/oncotarget.10035. Oncotarget. 2016. PMID: 27322425 Free PMC article.
• Conjugated linoleic acid induces apoptosis of murine mammary tumor cells via Bcl-2 loss.
  Ou L, Ip C, Lisafeld B, Ip MM. Ou L, et al. Biochem Biophys Res Commun. 2007 May 18;356(4):1044-9. doi: 10.1016/j.bbrc.2007.03.096. Epub 2007 Mar 26. Biochem Biophys Res Commun. 2007. PMID: 17400188 Free PMC article.
• Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs.
  Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, Franzoso G. Pham CG, et al. Mol Cell Biol. 2007 Jun;27(11):3920-35. doi: 10.1128/MCB.01219-06. Epub 2007 Apr 2. Mol Cell Biol. 2007. PMID: 17403902 Free PMC article.
• Likelihood models of somatic mutation and codon substitution in cancer genes.
  Yang Z, Ro S, Rannala B. Yang Z, et al. Genetics. 2003 Oct;165(2):695-705. doi: 10.1093/genetics/165.2.695. Genetics. 2003. PMID: 14573481 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal